Buprenorphine Transdermal System recalls
The FDA has published 2 recalls involving Buprenorphine Transdermal System since 2023. The latest was reported on 22 Mar 2023. Most were for potency & assay. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls2since 2023
Last 12 months0reported
Class I00% of total
Ongoing0latest 22 Mar 2023
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 0 0%Class III 2 100%
Why buprenorphine transdermal system is recalled
Companies
By year
All buprenorphine transdermal system recalls, newest first
2 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Buprenorphine Transdermal System, CIII 10 mcg/hour recalled | Aveva Drug Delivery Systems | Potency & Assay | Nationwide |
| Drug | CLASS III | Buprenorphine Transdermal System, CIII 20 mcg/hour recalled | Aveva Drug Delivery Systems | Potency & Assay | Nationwide |
Should you stop taking Buprenorphine Transdermal System?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.